^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    carfilzomib

    i
    Other names: PR-171, ONO 7057, ONO-7057, ONO7057, PR171, PR 171
    Company:
    Generic mfg.
    Drug class:
    Proteasome inhibitor
    Related drugs:
    4d
    Mezi-KD: A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New P2 trial
    |
    carfilzomib • dexamethasone • mezigdomide (CC-92480)
    4d
    Elo-KRd: Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma (clinicaltrials.gov)
    P2, N=46, Completed, University of Chicago | Trial completion date: Mar 2027 --> Dec 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    lenalidomide • carfilzomib • dexamethasone • Empliciti (elotuzumab)
    7d
    Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease (clinicaltrials.gov)
    P2, N=28, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting
    Enrollment open
    |
    carfilzomib • mezigdomide (CC-92480)
    10d
    KTX-MMSET-001: A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=125, Recruiting, K36 Therapeutics, Inc. | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    carfilzomib • dexamethasone • pomalidomide • mezigdomide (CC-92480) • gintemetostat (KTX-1001)
    11d
    A Study of NINLARO® in Chinese Adults With Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=72, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    bortezomib • Ninlaro (ixazomib) • carfilzomib
    28d
    IZALCO: A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carfilzomib • dexamethasone • dexamethasone injection • isatuximab subcutaneous (SAR650984 SC)
    28d
    Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=25, Completed, University of Chicago | Active, not recruiting --> Completed | N=101 --> 25
    Trial completion • Enrollment change
    |
    Darzalex (daratumumab) • carfilzomib • pomalidomide
    30d
    Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=5, Active, not recruiting, OHSU Knight Cancer Institute | Trial primary completion date: Apr 2026 --> Oct 2026
    Trial primary completion date
    |
    carfilzomib • pomalidomide • Sarclisa (isatuximab-irfc)
    30d
    Treatment of Antibody-Mediated Rejection (ABMR) With CarBel (clinicaltrials.gov)
    P2, N=100, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Initiation date: Oct 2025 --> Jan 2026
    Trial initiation date
    |
    carfilzomib
    1m
    Siltux-AMR: A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation (clinicaltrials.gov)
    P1, N=30, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carfilzomib • Sylvant (siltuximab)
    1m
    CarMob: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (clinicaltrials.gov)
    P1, N=18, Recruiting, Hackensack Meridian Health | Trial completion date: Oct 2025 --> Sep 2026 | Trial primary completion date: Oct 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • carfilzomib • melphalan • Neupogen (filgrastim) • dexamethasone injection
    1m
    Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=66, Recruiting, Hackensack Meridian Health | Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    carfilzomib • dexamethasone • iberdomide (CC-220)